Karyopharm Therapeutics
Jeremy Carey is a Clinical Trial Manager at Karyopharm Therapeutics Inc., with experience dating from February 2019 to the present, where significant roles included Senior Clinical Trial Associate and Clinical Trial Associate. Prior to this, Jeremy was a Clinical Site Manager at PAREXEL from December 2014 to November 2018, overseeing study implementation and protocol adherence at clinical sites. Key contributions included conducting Investigational Product Overview presentations for Phase III studies and finalizing IRB sites for other significant studies. Jeremy's career began at Target as a Backroom Team Member from 2011 to November 2014. Educational qualifications include a Bachelor of Science degree in Marine Biology from the University of Rhode Island and a Certificate in Biomanufacturing from Minuteman Technical Institute.
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).